Antisoma Share Discussion Threads

[ivor whopper] 03/6/2008 09:26

this is going to rise quite substantially, not on most peoples radar, yet.

[martincoops] 03/6/2008 09:11

Gents

Fingers has kindly done another ditty on ASM see link below. The £1 thread is an excellent thread and gives a great understanding on charts.

[azalea] 03/6/2008 08:33

I am in this morning with the rest of the herd.! I like the story, especially its strong cash position.

[gnomet2] 03/6/2008 02:12

Thanks farkyus. Ah, that explains the price drop. Nothing to do with the share
issue and purchase of hard-to -value assets - word had got out that the IC
were planning to rec it. At least they got their facts roughly straight this time,
though of course as 1411 has a potentially much larger market than leukaemia

ING has it as a buy and 62p price target today

[farkyus] 02/6/2008 22:08

Investor`s Chronicle - 2 June 2008

Antisoma announced that it has further data supporting its lung cancer treatment in an indication that represents just under half of sufferers, giving it a big competitive edge over the existing lung cancer treatment, Genentech's Avastin.
Lung cancer is the most common cause of cancer-related death in men and the second most common in women, and is responsible for about 1.3 million deaths annually. Antisoma is developing a lung cancer vaccine alongside partner Novartis that treats both squamous and non-squamous indications. In contrast, Genentech's Avastin only treats less severe non-squamous sufferers, who represent just over half of all sufferers.

Antisoma's shares rose just over 6 per cent to 23p in response to the positive
news, but it has been a bumpy ride; its shares have more than halved in the past 12 months.

In a rare move in the depressed UK biotech sector, two weeks ago Antisoma announced the £27m share based acquisition of US late stage vaccine developer Xanthus. KBC Peel Hunt analyst, Paul Cuddon, said that the transaction was "very positive" for Antisoma because of the strength of Xanthus' portfolio, with one drug at the marketing approval stage by the US Food and Drug Administration. He increased his valuation from 40p to 46p.


SHARE TIP UPDATE :

We advised buying Antisoma shares at 27p (11 April 2008). Antisoma still has high cash holdings, and with the result of its leukaemia treatment (AS1411) trial also due this quarter, we maintain our buy recommendation.

[davenic] 02/6/2008 15:29

Holdings in Antisoma




2 June 2008, London, UK: Antisoma plc (LSE: ASM; USOTC: ATSMY) has
received notification that BVF Partners L.P. has an interest in
26,093,543 ordinary shares of 1p each in Antisoma, representing 5.84%
of Antisoma's current issued ordinary share capital. Antisoma was
notified of the following in relation to the 26,093,543 shares:

1. These shares are registered in the name of Morgan Stanley & Co.
(14,660,000 shares) and Bear Stearns Securities Corp. (11,433,543
shares).

2. Further persons who are interested in these shares are BVF Inc.,
the general partner of BVF Partners L.P., and Mark Lampert, the
controlling shareholder of BVF Inc.

[latifs100] 02/6/2008 13:37

time to average down? hold from 40p

[davenic] 02/6/2008 09:02

Probably have not seen the news yet

[farkyus] 02/6/2008 08:39

why is there more sell than buys?strange

[gnomet2] 02/6/2008 00:27

Well, I don't like the empire building and fundraising
and don't blame the market for abreacting too if that's what's happening.
It might be an ok medium term strategy, but not good short term in this market.

Having said that though, if their acquisition were to be valued at what they paid for it then I think ASA404 is being valued by the market at only about 25 mill quid - which is far too low. Also, I think the new prostate data is definitely encouraging re likely survival benefit and development (with milestones) from Novartis.
Add to that the likelihood imo of good 1411 phaseII data within the month and I think the price should rebound strongly soon.

[scruff1] 01/6/2008 18:03

Me jumping the gun - still two hours to go

[scruff1] 01/6/2008 17:59

Not earth shattering but still yet more good news - usual presenatations have been largely uninformative. This seems a little more bullish. Why ain't we moving north? It is getting exciting. Unusual to get it on a Sunday.

[gnomet2] 30/5/2008 15:49

These are the abstracts. I think encouraging unless I'm missing something.
In lung cancer comfirms ok safe for both types (competitor avastin isn't)
In the prostate one actual tumour response rate differences reported for first time as 14% and that's very good.Time to progression pretty marginal, but that was the case with the v successful lung cancer trials too, so not that bothered.

Maybe the market is a bit bothered by lack of survival update(re prostate), but we were told last year not to expect that till July anyway.

Sorry, no time to comment further at mo

[robin_of_loxley] 30/5/2008 12:15

cheers the_doctor

[randsys] 30/5/2008 11:25

I don't believe there is anything wrong with ASM as a company, the share price is just suffering as a result of the markets in general. The Biotech sector is regarded as too risky for many at the moment, and there is considerable distressed selling for those who need to raise cash etc. This is just one stock that will require a lot of patience, and may well trade at lower levels than these before a recovery takes place. As a long term investor just ignore this short term volatility. As they say Rome wasn't built in a day! As ever DYOR etc.

[thepinkpanther] 30/5/2008 11:17

sorry to say it, but these look a damn good buy......

own opinion.

[the_doctor] 30/5/2008 09:35

R_O_L

To be honest, I've lost track a little.

Despite the ovarian hiccup, ASA404 appears promising.
Trouble is, oncology pipeline products are notorious at showing results in PII then failing in PIII. However, its somewhat based on proven mechanisms.

I think having a punt on this level again being support wouldnt be a bad idea?
Although, I'm unsure whether there are any near term drivers that will hold it up?
This recent drop is concerning and I'm sure shorters will be gunning for a break of support?

To make comparisons with OXB, I'm much more confident about OXB's early stage pipeline as a fall back if Trovax failed than I'd be about ASM's. Although that said, its literally been years since I really looked into ASM properly. My own strategy will be to hold off, research again and then, look to take advantage of 15p or so if that ever came. Thats not to say it isnt still good value here though.

Last trade I really considered was going short straight after the Novartis deal, given the way other stocks have been hit! (I didnt do it though)

[davenic] 30/5/2008 09:27

Cant say there is a shortage of news with these

[robin_of_loxley] 30/5/2008 08:46

the_doctor,

whats your view of the attractiveness of ASM at this price point over the short term?

regards

RoL

[cyclingnut] 30/5/2008 08:25

AM THINKING OF GETTING IN HERE but it is hard to call the bottom...

[scruff1] 30/5/2008 07:57

Anyone understand that RNS? What's a positive presentation? Can't pick anyhing out myself.